Clinical Trials Logo

Paranasal Sinus Neoplasms clinical trials

View clinical trials related to Paranasal Sinus Neoplasms.

Filter by:

NCT ID: NCT00098631 Completed - Clinical trials for Stage IV Squamous Cell Carcinoma of the Hypopharynx

Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

Start date: October 2004
Phase: Phase 2
Study type: Interventional

Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth. This phase II trial is studying how well lapatinib works in treating patients with recurrent and/or metastatic head and neck cancer.

NCT ID: NCT00096512 Completed - Tongue Cancer Clinical Trials

S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Start date: October 2004
Phase: Phase 2
Study type: Interventional

Sorafenib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It may also stop the growth of tumor cells by stopping blood flow to the tumor. This phase II trial is studying how well sorafenib works in treating patients with recurrent or metastatic head and neck cance

NCT ID: NCT00095641 Withdrawn - Clinical trials for Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity

S0225 Capecitabine in Treating Patients Who Have Undergone Surgery for Locally Recurrent or Persistent Head and Neck Cancer

Start date: n/a
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving capecitabine after surgery may kill any remaining tumor cells. PURPOSE: This phase II trial is studying how well capecitabine works in treating patients who have undergone surgery for locally recurrent or persistenthead and neck cancer.

NCT ID: NCT00095628 Completed - Clinical trials for Stage IV Squamous Cell Carcinoma of the Hypopharynx

SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Start date: January 2005
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well SB-715992 works in treating patients with recurrent or metastatic head and neck cancer. Drugs used in chemotherapy, such as SB-715992, work in different ways to stop tumor cells from dividing so they stop growing or die.

NCT ID: NCT00089362 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors

Start date: July 2004
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of alvespimycin hydrochloride in treating patients with metastatic or unresectable solid tumors. Drugs used in chemotherapy, such as alvespimycin hydrochloride, work in different ways to stop tumor cells from dividing so they stop growing or die.

NCT ID: NCT00081211 Terminated - Clinical trials for Stage IV Squamous Cell Carcinoma of the Hypopharynx

Intratumoral PV701 in Treating Patients With Advanced or Recurrent Unresectable Squamous Cell Carcinoma of the Head and Neck

Start date: April 2004
Phase: Phase 1
Study type: Interventional

Phase I trial to study the effectiveness of intratumoral (in the tumor) PV701 in treating patients who have advanced or recurrent unresectable squamous cell carcinoma (cancer) of the head and neck. Vaccines made from a specially-modified virus such as PV701 may make the body build an immune response to kill tumor cells while leaving normal cells undamaged. Injecting PV701 directly into the tumor may cause a stronger immune response and kill more tumor cells

NCT ID: NCT00068497 Completed - Clinical trials for Stage IV Non-small Cell Lung Cancer

Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer

Start date: August 2003
Phase: N/A
Study type: Interventional

This phase I trial is studying the side effects of gefitinib in treating patients with metastatic or unresectable head and neck cancer or non-small cell lung cancer. Gefitinib may stop the growth of cancer cells by blocking the enzymes necessary for their growth

NCT ID: NCT00055913 Completed - Clinical trials for Stage IV Squamous Cell Carcinoma of the Hypopharynx

Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Start date: March 2003
Phase: Phase 1/Phase 2
Study type: Interventional

This randomized phase I/II trial is to see if combining erlotinib with bevacizumab works better in treating patients who have recurrent or metastatic head and neck cancer. Erlotinib may stop the growth of tumor cells by blocking the enzymes needed for tumor cell growth. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. Combining erlotinib with bevacizumab may kill more tumor cells.

NCT ID: NCT00055770 Completed - Clinical trials for Stage IV Squamous Cell Carcinoma of the Hypopharynx

Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer

Start date: October 2002
Phase: Phase 1/Phase 2
Study type: Interventional

Phase I/II trial to study the effectiveness of combining erlotinib with docetaxel in treating patients who have locally advanced, recurrent, or metastatic head and neck cancer. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining erlotinib with docetaxel may kill more tumor cells.

NCT ID: NCT00033618 Completed - Tongue Cancer Clinical Trials

Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck

Start date: November 2002
Phase: Phase 2
Study type: Interventional

Randomized phase II trial to study the effectiveness of ixabepilone in treating patients who have metastatic or recurrent head and neck cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die